Little is known about the dynamics of human papillomavirus (HPV) during the follow-up of cervical intraepithelial neoplasia (CIN) 2/3 after biopsy.
test results-and, in some studies, high amounts (virus load) of HPV detected, resulting in concurrent cytologic abnormalities-increase the risk of cervical neoplasia [4, 5] . Prospective case-control studies typically record this information, in addition to colposcopic and cytologic status, and correlate these parameters with histologic outcome. The findings are required, in addition to histologic status, to determine the efficacy of drug candidates and to design appropriate standards of surveillance in clinical studies. They may also be important to the treatment of women with cervical neoplasia in clinical practice.
ZYC101a is an encapsulated plasmid DNA currently under investigation as a medical therapeutic for cervical intraepithelial neoplasia (CIN) and is derived from an HPV-specific formulation tested in an earlier phase 1 trial ( [6, 7] . Subjects with histologic-evaluation confirmed CIN2/3 lesions of the cervix were recruited to participate in a phase 2 double-blinded, randomized, placebo-controlled clinical trial. After a cervical diag- nostic punch biopsy confirming CIN2/3, eligible subjects were enrolled and randomized to either drug or placebo groups and, during the 6-month study period, were monitored by colposcopic, cytologic, and HPV testing. Persistence or resolution of disease was determined by use of a loop electrical surgical excision procedure (LEEP) performed at study exit.
Little is known about the dynamics of HPV in women with CIN2/3 lesions over time and the relationship of these patterns to the natural history of the lesions. Because HPV assays increasingly are relied on as surrogate markers of both infection and disease, a precise understanding of the relationship of HPV status may be critical to interpretation of outcome and, possibly, treatment strategies. This report summarizes the relationship between the HPV data obtained during 6 months of observation of women with CIN2/3 and histologic outcome. It demonstrates, for the first time, a close correlation between not only semiquantified HPV DNA levels but also the number of HPV types detected at study entry and during follow-up and with the resulting histologic outcome.
SUBJECTS, MATERIALS, AND METHODS
The ZYC101a protocol was approved by the institutional review boards at the respective study sites. Informed consent was obtained from all patients in the present study. Guidelines of the US Department of Health and Human Services and the Human Research Committee at Brigham and Women's Hospital, Boston, Massachusetts, were followed in the conduct of clinical research.
Procedures
Study protocol. Subjects were entered into the present study after receiving a histologic-evaluation confirmed diagnosis of CIN2/3. ZYC101a was administered intramuscularly (i.e., in the lateral quadriceps) as a single injection, once every 3 weeks for a total of 3 doses (weeks 0, 3, and 6). Subjects were monitored by colposcopic, cytologic, and HPV testing, at weeks 0, 6, 10, 18, and 26. Additional visits included colposcopic and cytologic evaluations, which were performed at weeks 3, 14, and 22. LEEP was performed at week 26.
Histopathologic evaluation. Histologic specimens obtained both at study entry (cervical punch biopsy) and at study exit (LEEP, a type of cone biopsy) were independently reviewed by 2 study pathologists and classified into the following categories: normal or reactive, low-grade squamous intraepithelial lesion (LSIL; CIN1; this included 1 case of nondiagnostic, atypical squamous epithelium); high-grade squamous intraepithelial lesion (HSIL; CIN2/3); and invasive carcinoma, according to published criteria [8, 9] . HSILs were not subdivided according to CIN2 and CIN3. Nonconcordant diagnoses were adjudicated by independent review of the slides by a third pathologist, and consensus was achieved by conference of all 3 study pathologists.
HPV testing. Samples were collected from the cervix by use of a broom-type device or a cytobrush/spatula, were placed into liquid-based cytology medium (ThinPrep; Cytyc), and were coded and submitted to a central laboratory for processing and cytologic evaluation. After cytologic evaluation, the residual samples were transported to the HPV testing laboratory for analysis.
For polymerase chain reaction (PCR) analysis, 1 mL of liquid-based sample (PreservCyt; Cytyc) was processed, as described elsewhere [10] . An aliquot was analyzed by PCR analysis, as described elsewhere, by use of MY09/MY11 primers designed to amplify a product from the L1 open-reading frame of a wide spectrum of HPV types [11] . The sensitivity of this assay for serially diluted control HPV DNA is ∼50 fg. HPV types were determined by use of restriction fragment-length polymorphism (RFLP), on the basis of comparisons with published sequence data. [12, 13] . When HPVs that were not classifiable on the basis of RFLP were detected, the HPVs were designated as "novel" and subclassified (e.g., as Novel A and Novel B) by restriction-fragment sizes, to facilitate tracking the HPV types during follow-up. Each assay and DNA purification included a set of positive and negative control samples.
For Hybrid Capture II (HC-II) analysis, 4 mL of the residual PreservCyt sample was analyzed by use of the HC-II assay (Digene) [14] . The HC-II assay for HPV DNA is a sandwich capture molecular hybridization assay that uses chemiluminescent detection to provide a semiquantitative result. The assay is calibrated to detect ∼4700 genome equivalents (or 1 pg/mL) of target HPV, represented by a relative light unit (RLU) measurement greater than or equal to the cutoff value calculated in each run by a series of standards. A measurement less than the cutoff value (1.0 RLU) was scored as negative.
Statistical analysis. Subjects were grouped according to their histologic outcome. x 2 analysis was used to test the null hypothesis of equal rates of histologic resolution in the different quartiles of virus load or HPV diversity at study entry. k-means clustering was performed on log 2 ratios of RLU/cutoff HC-II values, by use of a data centroid-based search for cluster initialization and Euclidean distance as a similarity measure. This method for initializing the centroids uses the first centroid to calculate the average of all profiles. The similarity between the centroid and all profiles is calculated by use of a Euclidean distance similarity measure. The profile that is least similar to the first centroid is picked to be the second centroid. The similarity between the second centroid and all remaining profiles is calculated. The profiles that are more similar to the second centroid than the first centroid are assigned to the second centroid and are then not investigated further. Of the remaining profiles, the profile that is least similar to the first centroid is picked to be the third centroid. The process is then repeated until the specified numbers of clusters are reached or until there are no more profiles left to assign. In the analysis of the HC-II data presented here, only 7 distinct profiles were found.
RESULTS

Viral status at study entry.
A total of 124 subjects (99%) were found to be HPV positive by either HC-II or PCR at study entry; 118 (95%) were found to be positive by both assays. PCR data at study entry and HC-II data at study entry were not available for 2 subjects and 1 subject, respectively. The distribution of HPV types identified by PCR is depicted in table 1. The frequency of HPV type 16 was 42% and, for types 16, 58, 52, 31, 18, 53, 56, and 33 combined, was 75%. Fifty percent and 6% of subjects were found to be positive for HPV 16 and HPV 18, respectively. At study entry, 4, 94, 24, and 3 subjects (3%, 75%, 19%, and 2%, respectively) were found to be positive for 0, 1, 2, and у3 HPV types, respectively. Approximately 8% of HPV types could not be classified and were labeled as "unclassified" (table 1) .
Interpretation of results of histopathologic evaluation. To determine the degree of interobserver agreement for distinguishing LSIL, HSIL, and nonlesional epithelium, a k statistic was computed between each pair of readers, with a separate set of cases being sent to the 3 readers. The results showed k values of 0.76 (between readers 1 and 3), 0.77 (between readers 1 and 2), and 0.84 (between readers 2 and 3), consistent with very-good-to-excellent agreement. Of 161 biopsy specimens evaluated by observers 1 and 2 at study entry, 16 (10%) required adjudication with a third observer.
Viral status at study entry versus histologic outcome. Table 2 depicts the relationship between viral status at study entry and histologic outcome at study exit. Subjects with a single HPV type at study entry more commonly exhibited normal histologic outcome at study exit. Ninety-three percent, 72%, and 68% of subjects with normal, CIN1, and CIN2/3 histologic outcomes at study exit, respectively, were found to be positive for a single HPV type at study entry.
Type-specific changes in viral status versus histologic outcome. Table 3 summarizes the number of new (additional) viral types identified subsequent to study entry, as a function of histologic outcome at study exit. Sixty-five percent, 24%, and 14% of subjects scored for 0, 1, and у2 additional HPV types, respectively. The frequency of у1 new HPV type was significantly higher in those with a histologic outcome of CIN1 at study exit (78%) than in those with CIN2/3 and normal outcomes (27% and 34%, respectively). Table 4 details changes in viral status (addition or disappearance of any HPV types), as a function of histologic outcome. Persistent detection of a single HPV type was significantly associated with a histologic outcome of CIN2/3 at study exit, compared with CIN1 and normal outcomes (62% vs. 22% and 27%, respectively). In contrast, replacement of the original HPV type with у1 new HPV type was significantly associated with a histologic outcome of CIN1 at study exit, compared with CIN2/3 and normal outcomes (39% vs. 6% and 7%, respectively). Clearing of all HPV types (negative result on assay at study exit) correlated significantly with a normal outcome, compared with CIN1 and CIN2/3 outcomes (50% vs. 0% and 3%, respectively). Change in HC-II level over time. In addition to the binary utility (positive/negative) application of the HC-II assay results, the RLU values can be used to approximate the relative levels of viral DNA (virus load) present in a sample [15] . The range of HC-II values obtained at study entry spanned 4 logs (0.27-2631). Fifty-five percent of the subjects were in the lower 10% range. The HC-II values at study entry were grouped in 4 value ranges, including 0-500, 501-1000, 1001-1500, and 11500 RLU, and were represented by 65%, 14%, 7%, and 12% of subjects, respectively. No significant correlation between HC-II level at study entry and histologic outcome at study exit was detected. However, HC-II levels at study exit were significantly associated with the presence of a squamous intraepithelial lesion (HSIL or LSIL), compared with no lesion (table 5) .
RLU values obtained at weeks 6, 10, 18, and 26 for each subject were compared to values at study entry (after biopsy). Each value was expressed as a fold change relative to the value at study entry, calculated on a log 2 transformation. Figure 1 segregates the 3 outcome groups into panels and plots each set of time points for a subject as a horizontal group of 4 squares, with green, black, and red signifying relative decrease, no change, and relative increase in signal, respectively, at the respective time points (gray represents missing data points). In general, normal histologic outcomes were associated with a decrease in RLU value (shown in green in figure 1 ), compared with the value at study entry.
To clarify further the relationship between fold change and histologic outcome, a k-means clustering analysis was performed to identify groups with a similar ratio of change patterns [16] . Four clusters (figure 1D-1G) were associated with CIN2/ 3 outcomes of 58%-80% of subjects. One cluster ( figure 1F ) demonstrated a downward shift in HC-II levels between weeks 18 and 26, despite a CIN2/3 outcome of 58%. Clusters showing an immediate downward shift in fold change from weeks 0 to 6 (figure 1H), weeks 6 to 10 (figure 1J), and weeks 10 to 18 (figure 1I) were associated with CIN2/3 outcomes of 25%-50%. In the first 4 groups combined ( figure 1D-1G) , the average frequency of a histologic outcome of CIN2/3, CIN1, and normal at study exit was 69%, 13%, and 17%, respectively. In the latter groups ( figure 1H-1J) , the respective percentages were 36%, 14%, and 50%. The differences in relative proportions of CIN 2/3, CIN 1, and normal outcomes, between these grouped clusters, were significant at . P p .05
DISCUSSION
On the basis of histologic evaluation (LEEP) at study exit, a patient with a prior biopsy-confirmed (study entry) diagnosis of CIN2/3 may be perceived as having undergone resolution of lesions, regression to a lower histologic grade, or persistence or progression in lesion grade. This perception is influenced by several scenarios that may occur before definitive excisional treatment: (1) the lesion may disappear spontaneously after biopsy; (2) the lesion may transiently persist but disappear before performance of LEEP; (3) the lesion may persist until performance of LEEP; (4) 11 lesion may be present, with persistence and/or resolution of у1 lesion; and (5) new HPV infections may develop after biopsy, which may or may not contribute to additional lesions at the time of performance of LEEP. An appreciation of these variables is critical to both a rational clinical response to unexpected findings and comprehending the cytologic and histologic data that form the basis for assessing novel therapies. The present study was designed to shed light on the dynamic of detectable HPV DNA infection and its influence on outcome during the follow-up of CIN2/3 lesions, by use of a semiquantitative measurement of virus load-that is, type-specific PCR.
HC-II data and PCR data correlated strongly, with over 95% concordance, and were complementary. PCR permitted assignment of specific HPV type and number at study entry and tracked additional viral encounters during the period after study entry. HC-II permitted approximation of virus load in RLUs, both at study entry (at the time of diagnostic biopsyconfirmed CIN2/3) and during the 6-month monitoring period before study exit. Accordingly, changes in virus load could be correlated with histologic outcome.
Because HC-II values cannot distinguish the relative individual contributions of у2 HPV types, the data offer only an estimation of total HPV. Overall, the average RLU values at study entry were not significantly different for the 3 major histologic classifications at study exit. However, k-means clustering identified 7 groups: 3 showed stable or increasing values relative to the value at study entry, 1 showed stable or increasing values followed by a reduction in relative values between weeks 18 and 26, and 3 showed reductions in relative HC-II values between study entry and week 10, with sustained reductions thereafter. In the first 4 groups combined ( figure 1D-1G) , a histologic outcome of CIN2/3, CIN1, and normal at study exit was seen in 69%, 13%, and 17% of subjects, respectively. In Table 4 . Persistence of human papillomavirus (HPV) versus histologic outcome at study exit. NOTE. Data are no. (%) of subjects. CIN, cervical intraepithelial neoplasia; cleared, elimination, by study exit, of all virus types detected at study entry; ND, not done; negative at study entry, samples negative by polymerase chain reaction but positive by Hybrid Capture II at study entry; persistent, detection of identical virus types at study entry and study exit; persistent/addition, detection at study exit of all virus types present at study entry plus additional new virus types; persistent/deletion, elimination at study exit of some but not all virus types detected at study entry; persistent/deletion/addition, detection at study exit of a subset of virus types present at study entry plus new virus types; replacement, elimination by study exit of all virus types detected at study entry, with the detection of an entirely new set of virus types.
a Includes 1 subject with a histologic outcome of atypical squamous epithelium at study exit. b x 2 , 75.74; . P ! .0001 NOTE. Differences in mean pre-study-exit HC-II values for high-grade squamous intraepithelial lesions (HSILs) or low-grade squamous intraepithelial lesions (LSILs) and normal histologic outcome at study exit are significant at (1-way analysis of variance). P p .01 the latter 3 groups ( figure 1H-1J ), the percentages of outcomes of CIN2/3, CIN1, and normal were 36%, 14%, and 50%, respectively. Temporal reductions in HC-II values between 1 set of time points only (between weeks 18 and 26) did not correlate with reversion to normal pathologic status. However, sustained reductions over у2 time points did significantly correlate with a normal outcome by x 2 analysis ( ). P ! .05 The present study is the first to report the concurrent use of virus load and type-specific PCR in the study of CIN2/3 lesions within a blinded clinical trial setting. Other studies have clearly shown that loss of detectable HPV precedes cytologic improvements by several months [17] [18] [19] . The frequency of sampling and the rigor of participant-inclusion criteria distinguish the findings reported here. These data help to explain the inconsistency between natural history and HPV load and imply that fluctuations in viral status are often due to the presence of additional detected HPV types. The type-specific HPV assay identified 3 associations that were germane to histologic outcome and that underscore the importance of HPV type-specific information during studies. Essentially all subjects were found to be positive by at least 1 of the assays; 1, 1, and 2 subjects in each of the outcome groups (CIN2/3, CIN1, or normal, respectively) were found to be HPV negative by PCR at study entry. The number of viruses detected at study entry also correlated significantly with histologic outcome. None of the subjects with a normal histologic outcome at study exit tested positive for 2 or 3 HPV types at study entry, compared with 30% and 23% of subjects with CIN2/3 and CIN1 outcomes, respectively (P ! ). The simplest explanation for this finding is that multiple .05 viral infections at study entry signify multiple lesions (or the potential for additional lesions) that may or may not resolve and, if so, may resolve at different rates.
The number of new HPV types detected over the course of the entire 6-month period further influenced histologic outcome, in this instance correlating strongly with an outcome of CIN1. Seventy-eight percent of subjects with an outcome of CIN1 encountered у2 HPV types during the study, compared with 34% and 27% of those with normal and CIN2/3 outcomes, respectively ( ). Moreover, although (as expected) neither P ! .05 CIN1 nor CIN2/3 outcomes were associated with clearing of HPV, the dynamics of HPV infection were distinctly different. The frequency of persistence of HPV type and replacement of HPV types was 62% and 6%, respectively, for CIN2/3 outcomes versus 22% and 39%, respectively, for CIN1 outcomes. The addition of new HPV types and/or replacement of HPV types with other types during the study, combined with a downward shift in morphologic grade at the end of the study, strongly support the postulate that additional detected HPV infections produced new lesions (CIN1), whereas others (CIN2/3) resolved. Prior studies have linked "recurrences" after ablative therapy to HPV types other than the original, and, similar to those in the present study, most were associated with CIN1 [20] . The present study has shown that diagnostic punch biopsy, like ablation, may be followed by changes in viral status and lesion grade and that these changes occur over a relatively short (6-month) period. Whether these changes in viral status signify new viral exposures during the follow-up period or an increase in the level of additional HPV types to the threshold of detection cannot be determined.
There are 3 potential explanations for a histologic outcome of CIN1 at study exit after a diagnosis of CIN2/3 by punch biopsy at study entry: (1) misclassification of the sample obtained at study entry, (2) reversion of CIN2/3 to CIN1 during the study, and (3) coexisting or subsequent infection by a second HPV type that produces CIN1. The results of the present study suggest that the third scenario is most common; that is, that additional HPV infections and new lesions will develop Figure 1 . Changes in Hybrid Capture II (HC-II) levels over time and the detection of patterns with predictive value. The ratio of change in HC-II level at each visit was calculated in reference to levels measured at study entry. Calculated ratios were then log 2 transformed and plotted in a heat map, with increasing levels shown in red, decreasing levels shown in green, no change shown in black, and missing data shown in gray. Each row represents a single subject, and each column represents a study visit (weeks 6-26). A, All subjects with cervical intraepithelial neoplasia (CIN) 2/3 at study exit; B, all subjects with CIN1 at study exit; C, all subjects that were normal at study exit. k-means clustering was performed to detect similar patterns in change over time (D-J). The percentage of histologic outcomes associated with each cluster is shown as an embedded pie chart.
after a diagnosis of CIN2/3 by biopsy. Such infections will not be appreciated without integrating both histologic grade and HPV type-specific information into the data analysis. An appreciation of these phenomena is necessary if the practitioner is to comprehend unexpected histologic outcomes at study exit. Moreover, correlation of type-specific HPV, histologic, and cytologic data is critical to determining the efficacy of HPVspecific therapeutics for early cervical neoplasia.
